Color-Coded Microsphere Assay for Multiplex Alzheimer Biomarker Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for quantifying Alzheimer's biomarkers such as Aβ40, Aβ42, p181Tau, p217Tau, NFL, and GFAP are costly, require high technical expertise, and lack high-throughput capability, posing barriers for large-scale studies, especially in resource-limited settings.
Innovation Solution
A bioassay system utilizing color-coded microspheres coated with specific capture agents for Aβ40, Aβ42, p181Tau, p217Tau, GFAP, and NFL, combined with a fluidic and detection system for multiplexed quantification, and normalization using control microspheres to reduce variability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If Luminex xMAP-based technology is used for multiplex quantification, then multiplexing capability and throughput are improved, but cost and technical expertise requirements increase
Solution Approach 1:
The patent employs Luminex xMAP technology which uses color-coded microspheres with unique spectral signatures to simultaneously detect multiple analytes (Aβ40, Aβ42, p181Tau, p217Tau, NFL, GFAP) in a single assay. This multi-functional approach allows one system to perform what would traditionally require multiple separate assays, achieving high-throughput capability while maintaining standardized operational procedures that reduce the need for specialized technical expertise for each individual biomarker measurement
2Ease of operation
If multiple separate assays are used for each biomarker, then ease of operation is improved, but productivity and throughput decrease
Solution Approach 1:
The patent combines the measurement of six different Alzheimer's disease biomarkers into a single multiplexed assay using Luminex xMAP technology. Color-coded microspheres coated with specific capture agents for each biomarker are mixed with the sample, allowing simultaneous detection of Aβ40, Aβ42, p181Tau, p217Tau, NFL, and GFAP. This merging of multiple assays into one maintains operational simplicity while dramatically increasing throughput and reducing the time and resources required for comprehensive biomarker profiling
3Measurement precision
If high sensitivity detection is implemented, then measurement precision is improved, but device complexity and cost increase
Solution Approach 1:
The patent employs fluorescence-based detection instead of more complex mechanical or manual detection methods. The Luminex system uses fluorescently labeled microspheres and automated fluorescence reading to achieve high sensitivity detection of biomarkers at low concentrations in plasma and serum. This substitution of mechanical/manual detection with optical fluorescence detection maintains measurement precision while reducing operational complexity and enabling automated high-throughput processing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate, cost-effective, and high-throughput multiplex quantification of Alzheimer's biomarkers in plasma and serum, with high diagnostic accuracy and correlation with CSF levels, facilitating large-scale screening and early diagnosis.
Implementation Method 1
a first set of microspheres distinguishable by a first unique color code generated by internal dyes
Implementation Method 2
the reporter molecules configured to emit a detectable reporter fluorescence upon excitation
Implementation Method 3
a detection system including a flow cell and capable of exciting and reading fluorescence of each internal dye and the detectable reporter fluorescence
Implementation Method 4
coated with a specific capture agent that binds to Aβ40, a second set of microspheres distinguishable by a second unique color code generated by internal dyes and is coated with a specific capture agent that binds to Aβ42
Data Source
AI summary
A bioassay system for multiplexed detection and quantification of multiple analytes (e.g., Aβ40, Aβ42, pTau181, p217Tau, GFAP, and NFL) in a biological sample is provided. The bioassay system includes a plurality of sets of color-coded microspheres. Each set of microspheres is distinguishable by a unique color code generated by internal dyes. The bioassay system includes a first set of control microspheres attached to mouse polyclonal IgG to correct for a background of individual specimens and a second set of control microspheres configured to capture a synthetic peptide to normalize for well-to-well variations. Bioassay system also includes a fluidic system configured to mix the sample with the plurality of sets of color-coded microspheres to allow for specific binding between analytes and their corresponding capture agent among other analytes and a detection system for exciting and reading fluorescence of the internal dyes and a reporter fluorescence indicative of analyte binding.